# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 8-K

**CURRENT REPORT**
**PURSUANT TO SECTION 13 OR 15(D)**
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 20, 2020**

# EyePoint Pharmaceuticals, Inc.

**(Exact name of registrant as specified in its charter)**

| **Delaware** | **000-51122** | **26-2774444** |
|---|---|---|
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

**480 Pleasant Street**
**Watertown, MA 02472**
**(Address of Principal Executive Offices, and Zip Code)**

**(617) 926-5000**
**Registrant's Telephone Number, Including Area Code**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| **Common Stock, par value $0.001** | **EYPT** | **The Nasdaq Stock Market LLC** |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On February 20, 2020, EyePoint Pharmaceuticals, Inc. posted an updated corporate presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

| Exhibit No. | Description |
|---|---|
| 99.1 | Corporate Presentation, dated February 20, 2020 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EYEPOINT PHARMACEUTICALS, INC.**

Date: February 20, 2020

/s/ Nancy Lurker
Nancy Lurker
President and Chief Executive Officer

Exhibit 99.1

# INVESTOR PRESENTATION

**FEBRUARY 2020**

NASDAQ: EYPT

EYEPOINT PHARMACEUTICALS

# FORWARD LOOKING

Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors only. Nothing in this presentation should be construed as promoting the use of YUTIQ®, DEXYCU® or any of our product candidates. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and YUTIQ 50; the potential for EYP-1901 as a vital, new six-month treatment for serious eye diseases, including wet AMD, DR and RVO; our expected financial results for the fourth quarter and full fiscal year ended December 31, 2019 and our longer term financial and business goals, are forward-looking statements. Further, our preliminary fourth quarter and full year 2019 revenue results are preliminary and subject to adjustment in the ongoing review procedures by our independent registered public accounting firm. In addition, any financial projections and other estimates contained herein are forward-looking statements with respect to our anticipated performance. Such forward-looking statements, financial projections and estimates are as to future events and are not to be viewed as facts, and reflect various assumptions of management of the Company and are subject to significant business, financial, economic, operating, competitive and other risks and uncertainties and contingencies (many of which are difficult to predict and beyond our control) that could cause actual results to differ materially from the statements included herein. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of our preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approval; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema; Alimera's ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for diabetic macular edema; Alimera's ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreements with Equinox Science, LLC; termination or breach of current license agreements, including our agreement with Equinox Science, LLC; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

# AN EMERGING LEADER IN OPHTHALMOLOGY

EyePoint Pharmaceuticals

DEXYCU (dexamethasone intraocular suspension) 9%

Postoperative inflammation following ocular surgery

0.18 mg YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

Chronic non-infectious uveitis affecting the posterior segment of the eye

- Pipeline leveraging proven Durasert® technology with innovative programs targeting 6-month Wet AMD, Diabetic Retinopathy, Retinal Vein Occlusion, and Posterior Uveitis opportunities
- YUTIQ® and DEXYCU® launched in 2019 driving a growing commercial business
- Focused on organic and inorganic growth and select product acquisition to build top-line revenue and expand pipeline
- Strategic focus to become go-to partner for commercialization in ophthalmology
- Veteran executive team with deep experience in commercial product launches and drug development

# PIPELINE

EYEPOINT PHARMACEUTICALS

| Program | Preclin. | Phase 1 | Phase 2 | Phase 3 | Commercial | Rights |
|---|---|---|---|---|---|---|
| **DEXYCU®**<br>post-operative inflammation | | | | | Launched/J-Code In-Place | WW |
| **YUTIQ®**<br>three-year treatment for chronic non-infectious uveitis affecting the posterior segment | | | | | Launched/J-Code In-Place | U.S.[1] |
| **YUTIQ® 50 (sNDA)**<br>6-month treatment for chronic non-infectious uveitis affecting the posterior segment | | | ~60 patient 6-month trial planned | | | WW |
| **EYP-1901 - Durasert® Tyrosine Kinase Inhibitor (TKI) Vorolanib**<br>6-month treatment for wAMD, RVO, DR | IND enabling studies | | | | | WW[2] |

[1] Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA with a royalty payable to EyePoint.
[2] Excludes China, Hong Kong, Macau and Taiwan

# PROVEN OCULAR DELIVERY TECHNOLOGIES

## Durasert® and Verisome®: Proprietary, FDA Approved Technologies

### Durasert®

**Ocular insert for long-term delivery of small molecules**

**Approved products[1]:**

- YUTIQ® (2018, EyePoint) - *Posterior Segment Uveitis*
- ILUVIEN® (2014, Alimera) - *DME*
- RETISERT® (2005, B&L) - *Uveitis*
- VITRASERT® (1996, B&L) - *CMV retinitis*

### Verisome®

**Microsphere suspension short-term delivery of small and potentially large molecules**

**Approved products:**

- DEXYCU® (2019, EyePoint)

[1]- All products utilize Durasert® non-erodible technology

# RECENT NEWS

## Q4 2019 Momentum Continues into 2020

- Vorolanib license completed
  - TKI molecule in EYP-1901 brings promising efficacy signal from prior human clinical trials as oral therapy
  - License agreement finalized after completion of initial intra-vitreal safety and PK studies of EYP-1901 by EyePoint
  - Advancing as six-month intra-vitreal treatment using bioerodible Durasert® technology
  - Positive pre-IND Type B meeting completed with FDA (Jan 2020) clarifying the pathway for a phase 1 clinical trial
  - GLP Tox to begin in Q1
- YUTIQ®50 *(6-month)* - regulatory and approval pathway clarified with FDA
- Preliminary Q4 and full-year 2019 revenues announced with strong revenue and customer demand growth for both DEXYCU® and YUTIQ®
- DEXYCU® licensed for China expanding relationship with China partner for YUTIQ®

# EYP-1901 – 6-Month Durasert® Vorolanib - Tyrosine Kinase Inhibitor (TKI)

***Opportunity in wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion***

EyePoint Pharmaceuticals

# EYP-1901 – Addressable Market Sizes (U.S.)

EYEPOINT PHARMACEUTICALS

## Wet AMD





## Retinal Vein Occlusion (RVO)





## Diabetic Retinopathy (DR)







(1) Assumes percentage treated with anti-VEGF is same for Macular Edema from RVO, and RVO without Macular Edema
(2) Includes percentage treated with lasers and steroids
Sources: KOL insights; Datamonitor 2019; Kodiak Sciences; Cowen Therapeutic Categories Outlook 2019; AAO; Centers for Disease Control; Global Data

# EYP-1901 – VOROLANIB RECEPTOR TARGETING

## Vorolanib Inhibits VEGFR, PDGFR, c-Kit, CSF1R and Flt-3

**Biochemical Selectivity (IC50 in µM)**

| ID | VEGFR | PDGFR | Flt-3 | C-KIT | RET | AMPK |
|---|---|---|---|---|---|---|
| Sunitinib | 0.043 | 0.16 | 0.003 | 0.16 | 0.037 | 0.21 |
| Vorolanib | 0.052 | 0.26 | 0.006 | 0.16 | 0.15 | 1.23 |

- Vorolanib and sunitinib target the angiogenic receptors VEGFR and PDGFR with similar potency
- Importantly, vorolanib is significantly less potent against RET and AMPK
  - Potential for reduced hypothyroidism and fatigue toxicities versus sunitinib
  - Reduced off-target activity should translate to reduced toxicity relative to sunitinib in patients

- The enzymes VEGFR-2, PDGFRβ, and Flt-3 are pro-angiogenic proteins
- Each of these important targets is strongly inhibited by both vorolanib and sunitinib with comparable IC50 values

# VOROLANIB CLINICAL HISTORY[1]

EyePoint Pharmaceuticals

## Molecule Demonstrates Positive Efficacy Signal From Oral Delivery wAMD Trials

### Phase 1 Trial – 24 Weeks

| | |
|---|---|
| **Visual Acuity (BCVA)** | • Despite low retreatment rates, best-corrected visual acuity was maintained to within four letters of baseline at the 24-week end point or improved in all except 1 participant.[2]<br>• Mean change was +3.8 +/- 9.6 letters (n=25 completers) |
| **Anti—VEGF Rescue Injections** | • 60% of patients (15 of 25) required no injections while on 24-week study<br>• The mean time to the first rescue injection was 130 days in the 10 participants who completed the study and required an injection[3] |
| **Central Retinal Thickness** | • Mean OCT thickness in completers was reduced by -50 +/- 97 µm[3]<br>• Mean OCT thickness in treatment-naïve patients was reduced by ~80 µm[4] |

1 – Study completed by Tyrogenix, Inc.
[2] Jackson TL et al. JAMA Ophthalmology July 2017 Volume 135, Number 7, 2017 – page 766
[3] -Jackson TL et al. JAMA Ophthalmology July 2017 Volume 135, Number 7, 2017 – page 765
[4] -Jackson TL et al. JAMA Ophthalmology July 2017 Volume 135, Number 7, 2017 – page 765 –figure 4

# VOROLANIB CLINICAL HISTORY[1] - wAMD

EYEPOINT PHARMACEUTICALS

## Phase 1 Oral Delivery Trial - Preliminary Evidence of BCVA Improvements and Ocular Safety

**Subjects Who Completed 6 Months Without Rescue Injections (N=15)**


**Mean Change in ETDRS Score ± SEM from Baseline**

- 15 completers (60%) with no rescue through 24 weeks (shown in graph)
- 25/35 completed with 10 discontinued due to systemic AEs and non-drug related events
- No significant ocular AEs

1 – Study completed by Tyrogenix, Inc.

# VOROLANIB CLINICAL HISTORY[1] - wAMD

## Phase 1 Oral Delivery Trial - Reduced Rescue Injections over 6 months




- The graphs shows the mean number of intravitreal anti-vascular endothelial growth factor (VEGF) rescue injections that participants required in each of the X-82 groups.
- The completers' group (red) comprises the 25 participants who reached the 24 week endpoint, and the overall group (blue) comprises all 35 participants.

- Clear dose response with daily oral dosing between 50 mg and 200 mg
- Subjects dosed at 300 mg dropped out due to GI AEs attributed to oral dosing

X-82 is prior program name for vorolanib
1 – Study completed by Tyrogenix, Inc.

# VOROLANIB CLINICAL HISTORY[1]

EYEPOINT PHARMACEUTICALS

## Phase 1 Oral Delivery Trial – Central Subfield Thickness Maintained or Reduced over 6 months

### Subjects Who Completed 6 Months Treatment




1 – Study completed by Tyrogenix, Inc.
Mean ± Standard Error.

# VOROLANIB CLINICAL HISTORY[1]

## Phase 2b Oral Delivery Trial in wAMD

**Double-masked, placebo-controlled dose finding study evaluating 50, 100 and 200 mg daily orally vs. placebo in wAMD patients**

- Diagnosed for >6 months and receiving IVT anti-VEGF at least every 8 weeks for the past two injections with evidence of reduction in macular fluid or thickness by OCT

**Objective: To determine the safety and efficacy**

- Primary endpoint: The mean change in ETDRS visual acuity score at week 52
  - Required by FDA. Not expected to be different as all pts would be treated prn
- Secondary endpoint: The mean number of anti-VEGF injections by week 52

**Pre-defined rescue criteria with intravitreal anti-VEGF therapy**

- Assessment was made at each follow up visit, every 4 weeks, to determine if rescue therapy with an anti-VEGF was needed

1 – Study completed by Tyrogenix, Inc.

# VOROLANIB CLINICAL HISTORY[1]

## Phase 2b Oral Delivery Trial in wAMD[2]

EYEPOINT PHARMACEUTICALS

**Prematurely Terminated by DSMB Due to Negative Systemic AEs**
**No Significant Ocular AEs Were Reported**

- Study started in March 2015 and enrolled 157 patients
- Randomized 40, 39, 39 and 39 patients at 50, 100, 200 mg and placebo respectively
- The trial was expected to take place for 56 weeks (52 weeks with additional 4 weeks of follow up)
- Study stopped prematurely at the second interim analysis (36 weeks follow up) based on concern of gastrointestinal and hepatobiliary toxicity[3]

1 – Study completed by Tyrogenix, Inc.
[2] Cohen M et al. The Retina Society. 52nd Annual Scientific Meeting. London, September 11-15, 2019.
[3] Cohen M et al. The Retina Society. 52nd Annual Scientific Meeting. London, September 11-15, 2019 – page 101

# VOROLANIB CLINICAL HISTORY[1]

## Phase 2b Oral Delivery Trial in wAMD

EYEPOINT PHARMACEUTICALS

**BCVA was Stable Through 12-Months in Patients Already Controlled by Current Anti-VEGF Therapies**

Protocol X82-OPH-201
Study Population: ITT Population

| | X-82 100 mg N=39 | X-82 200 mg N=39 | Placebo N=39 | X-82 50 mg N=40 | Overall N=157 |
|---|---|---|---|---|---|
| Change in VA from Baseline at Week 52 | | | | | |
| n | 19 | 17 | 22 | 23 | 81 |
| Mean | -0.9 | 1.7 | -0.3 | 0.2 | 0.1 |
| SD | 6.57 | 5.58 | 10.63 | 4.14 | 7.15 |
| Median | -3.0 | 2.0 | 1.5 | 0.0 | 1.0 |
| Min, Max | -15;9 | -13;9 | -18;23 | -8;10 | -18;23 |

X-82 is prior program name for vorolanib
1 – Study completed by Tyrogenix, Inc.

# VOROLANIB CLINICAL HISTORY[1]

## Phase 2b Oral Delivery Trial in wAMD

**BCVA stabilization was achieved with ~50% fewer rescue interventions vs. placebo**

| | X-82 100 mg N=39 | X-82 200 mg N=39 | Placebo N=39 | X-82 50 mg N=40 | Overall N=157 |
|---|---|---|---|---|---|
| Number of anti-VEGF injections per year* | | | | | |
| n | 39 | 39 | 39 | 40 | 157 |
| Mean | 6.0 | 4.7 | 8.1 | 6.7 | 6.4 |
| SD | 3.69 | 3.59 | 3.90 | 4.64 | 4.12 |
| Median | 6.3 | 5.0 | 8.6 | 6.2 | 6.3 |
| Min, Max | 0.0;12.5 | 0.0;12.2 | 0.0;13.0 | 0.0;22.0 | 0.0;22.0 |
| For subjects who were followed at least 6 months, number of anti-VEGF injections per year* | | | | | |
| n | 30 | 26 | 33 | 34 | 123 |
| Mean | 6.0 | 4.4 | 8.4 | 6.5 | 6.4 |
| SD | 3.68 | 3.26 | 3.74 | 4.59 | 4.09 |
| Median | 5.8 | 4.6 | 9.0 | 6.1 | 6.0 |
| Min, Max | 0.0;12.5 | 0.0;11.2 | 0.0;13.0 | 0.0;22.0 | 0.0;22.0 |

* Normalized for the number of months on study. The normalization is calculated as (number of anti-VEGF injections received)*12/(time on study in months), where time on study (months) = (date of week 52 visit/early discontinuation - date of randomization +1)/30.4375. For those missing their week 52 visit, the last visit before week 52 is used.

X-82 is prior program name for vorolanib

1 – Study completed by Tyrogenix, Inc.

# EYP-1901 –ACTIVITY IN VALIDATED LASER CNV MINI PIG MODEL[1]

EyePoint Pharmaceuticals

## Observed Efficacy Signal in Fluorescein Angiography (FA) Results Using 6-month EYP-1901 Insert




[1] – Study completed by EyePoint Pharmaceuticals, Inc.
CTLF = Corrected Total Lesion Fluorescence Integrated Density (Area of lesion X Mean fluorescence background readings)
High = high dose; Low = low dose
D = day

# EYP-1901 – DEVELOPMENT PLAN

EyePoint Pharmaceuticals

## Preparing for Phase 1 Study

- Type B Pre-IND meeting completed with FDA (Jan 2020)
- Preliminary safety toxicity study in mini pig complete and supportive
- Non-GLP rabbit PK and safety complete
  - 2-week data demonstrated tissue concentration above IC50 range
  - 2 month complete, data supportive to initiate GLP tox program
- GLP tox study expected to begin in Q1 2020
- Current Phase 1 trial timeline anticipates initial data in 2H of 2021

# YUTIQ50

EyePoint Pharmaceuticals

# YUTIQ®50 – DEVELOPMENT PLAN

EyePoint Pharmaceuticals

## 6-month Treatment for Chronic Non-Infectious Uveitis Affecting the Posterior Segment

- ~60 patient trial; 2:1 randomization
- 6-Month release data results comparable to 3-year YUTIQ
- Anticipate filing under sNDA with 6-month approval clock

# Commercial Programs

EyePoint Pharmaceuticals

# TWO COMMERCIAL PRODUCTS LAUNCHED IN 2019

EYEPOINT PHARMACEUTICALS

DEXYCU® (dexamethasone intraocular suspension) 9%

**Postoperative inflammation following ocular surgery**

- 33 dedicated KAMs targeting high-volume ambulatory surgical centers (ASCs)
- Permanent and specific J-Code with solid reimbursement experience

0.18 mg YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

**Chronic non-infectious uveitis affecting the posterior segment of the eye**

- 12 dedicated KAMs targeting uveitis specialists – planned increase to 18 during 2020
- Permanent and specific J-Code effective as of October 1, 2019

# DEXYCU® - Significant Market Opportunity ~$2B

## U.S. Cataract Surgery Very Large and Growing

**Step 1**

**Diseased lens is removed**




**Step 2**

**Intraocular lens is inserted**




**Step 3**

**Intraocular lens is positioned**




- Steroids typically needed to prevent post-operative inflammation

**3.8 Million***

**Cataract Surgeries in 2018**

- 8% annual growth rate in the U.S.
- Most performed surgery in the U.S.

**Baby boomers; longer life expectancy with greater access to healthcare**

**Improvements in technology**

**Improved outcomes**

* Based upon company estimates for 2018.
Source: imaged from the American Optometric Association.

# DEXYCU® MARKET OPPORTUNITY

EyePoint Pharmaceuticals

## Post-cataract Treatment Regimen Requires Multiple Daily Eyedrops




**Up to 100 Drops Over Four Weeks**

*Source: Vigamox/Besivance product labeling (not specifically indicated for this use, but are commonly prescribed for use).
**Source: Prolensa/Bromday product labeling (not specifically indicated for this use, but are commonly prescribed for use).

### Physician Perspective

- Poor patient compliance with drops could lead to **poor outcomes**
- Patient call backs are time consuming and **disruptive to physician office**
- Patients/caregivers are **frustrated and confused with regimen**

# DEXYCU®

EyePoint Pharmaceuticals

## First and Only FDA-approved Single-dose, Sustained-release, Intracameral Steroid for the Treatment of Postoperative Inflammation Following Ocular Surgery

- Single dose (5µL) administered in the posterior chamber (behind the iris) at the end of surgery
- Encapsulated in bioerodible Verisome® technology for extended release of dexamethasone

### Verisome® Technology



**Dexamethasone**

Detectable up to 22 days after single injection[1]

### DEXYCU® Kit


### DEXYCU® Placement



Suspension placed behind the iris

[1] Wong V. et al. Pharmacokinetic Study of 10090 in the Anterior Chamber of Rabbits (2013).
Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com.

# DEXYCU DEMONSTRATION

Please see video at company website:
https://eyepointpharma.com/case-study-series/

# DEXYCU®

## Statistically Significant Inflammation Reduction

### Patients with Anterior Chamber Cells (ACC) Clearing at Each Visit




Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com.

# DEXYCU®

EYEPOINT PHARMACEUTICALS

## IOP Elevation Versus Placebo Not Clinically Significant




Data on file. Phase III Study 13-04. Post hoc analysis.

# DEXYCU®

## Phase 3 Study – Safety Results

| Safety, n (%) | Placebo N=80 | 517 mcg N=156 |
|---|---|---|
| Any TEAE in Study Eye | 51 (63.8) | 72 (46.2) |
| Any Ocular SAE in Study Eye | 0 | 0 |
| Any Non-ocular SAE | 4 (5.0) | 4 (2.6) |
| Study Eye AEs Occurring in ≥5% of at Least One Active Treatment Group | | |
| Intraocular Pressure Increased | 7 (8.8) | 21 (13.5) |
| Corneal Edema | 8 (10.0) | 12 (7.7) |
| Eye Pain | 7 (8.8) | 4 (2.6) |
| Anterior Chamber Inflammation | 10 (12.5) | 8 (5.1) |
| Dry Eye | 0 | 6 (3.8) |

Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com.

# DEXYCU® SALES PROCESS

**Average Time (weeks) to Account Re-Order**


1. **Introduce**
   Introduce DEYXCU and its clinical and safety data to target physician
2. **Educate**
   Educate the ASC where physician operates about DEXYCU profile
3. **Sample**
   Schedule a physician and staff DEXYCU trial and training
4. **Order**
   ASC places first order and files DEXYCU reimbursement claim
5. **Re-Order**
   Once reimbursement is confirmed, schedule additional patients for DEXYCU and provide ongoing ASC surgical support

# DEXYCU® 2019 PERFORMANCE

## Month Over Month Growth Accelerating

- 4Q2019 customer demand increased 86% as compared to 3Q2019
- 4Q2019 net revenue in $2.8–$3.1M range
- FY2019 net revenue in $4.4–$4.7M range

# DEXYCU®

EYEPOINT PHARMACEUTICALS

## Market Potential Based on Account Penetration Through 12/31/19




**Value of Target Accounts**

**Value of Trained Accounts**

**Value of Current ASC Accounts Ordering**

ASC: Ambulatory Surgical Center
Data based on internal estimates

# YUTIQ® Market

- Uveitis *is*:
  - Inflammation of the Uveal tract (iris, ciliary body, choroid), or adjacent structures (lens, retina, vitreous, optic nerve)
  - Acute or Chronic
  - A precursor to severe vision loss or blindness
  - Often lifelong




**~60K–100K**

**Patients in the U.S. with Chronic Non-infectious Posterior Segment Uveitis**

- ~30,000 new cases of blindness per year in the U.S.
- 3rd leading cause of blindness in the U.S.

EYEPOINT PHARMACEUTICALS

## YUTIQ® Is Designed to Deliver a Sustained Release of Fluocinolone for Patients with Chronic Noninfectious Posterior Uveitis for Up To 36 Months

### Durasert® Technology


### Packaging


### YUTIQ Placement



# YUTIQ®

## Recurrence Rate at Six and Twelve Months vs Sham

### Study 1 (Recurrence Rate at 6 and 12 Months)




### Study 2 (Recurrence Rate at 6 and 12 Months)




YUTIQ Sham*

* Sham includes standard of care.
Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com

# YUTIQ®

EyePoint Pharmaceuticals

## Single Insert Reduced Probability of Uveitis Recurrence Through 36 Months

**ITT Population**




**YUTIQ Median Time to First Recurrence: 1,051 Days**

3 years

Note: Sham patients include patients that received rescue therapy.

# YUTIQ®

## Safety – Select Adverse Events

| Safety, n (%) | YUTIQ® n=226 | Placebo n=94 |
|---|---|---|
| Visual Acuity Reduced | 33 (15%) | 11 (12%) |
| Macular Edema[1] | 25 (11) | 33 (35) |
| Uveitis | 22 (10) | 33 (35) |
| Conjunctival Hemorrhage | 17 (8) | 5 (5) |
| Eye Pain[2] | 17 (8) | 12 (13) |
| Hypotony of the Eye[3] | 16 (7) | 1 (1) |
| Anterior Chamber Inflamm. | 12 (5) | 6 (6) |
| Dry Eye | 10 (4) | 3 (3) |

[1] Includes macular edema and cystoid macular edema
[2] Includes eye pain and procedural pain
[3] Includes hypotony, intraocular pressure decreased and procedural hypotension
Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com

# YUTIQ® 2019 PERFORMANCE

## Strong Monthly Demand Growth Continues

- 4Q2019 customer demand increased 43% as compared to 3Q2019
- 4Q2019 net revenue in $4.1–$4.5M range
- FY2019 net revenue in $11.4–$11.8M range

# KEY ACCESS AGREEMENTS TO EXPAND PRODUCT REACH

EyePoint Pharmaceuticals

VA | U.S. Department of Veterans Affairs

- DEXYCU® and YUTIQ® added to the Federal Supply Schedule
- Access to U.S. veterans and other federal agencies
- Nine Million VA beneficiaries added

vizient™

- Three-year agreement for DEXYCU®
- Vizient's network includes more than 50% of the nation's acute care providers, including 95% of the nation's academic medical centers, and more than 20% of ambulatory care providers

**One of Largest Integrated Delivery Systems in the U.S.**

- DEXYCU® available to its 8.5 million patients
- 2-year contract includes California, Washington, Georgia, Colorado and Mid-Atlantic states

# AN EMERGING LEADER IN OPHTHALMOLOGY

EyePoint Pharmaceuticals

DEXYCU (dexamethasone intraocular suspension) 9%

Postoperative inflammation following ocular surgery

0.18 mg YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

Chronic non-infectious uveitis affecting the posterior segment of the eye

- Pipeline leveraging proven Durasert® technology with innovative programs targeting 6-month Wet AMD, Diabetic Retinopathy, Retinal Vein Occlusion, and Posterior Uveitis opportunities
- YUTIQ® and DEXYCU® launched in 2019 driving a growing commercial business
- Focused on organic and inorganic growth and select product acquisition to build top-line revenue and expand pipeline
- Strategic focus to become go-to partner for commercialization in ophthalmology
- Veteran executive team with deep experience in commercial product launches and drug development